Literature DB >> 7563004

Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.

G J Van Asselt1, J H Sloos, R P Mouton, C P Van Boven, J A Van de Klundert.   

Abstract

The susceptibility of 180 clinical isolates of Streptococcus pyrogenes from six regions of The Netherlands to the macrolide antibiotics azithromycin, clarithromycin, erythromycin and roxithromycin was analysed. The results of a microbroth MIC method, the E-test method and a disk diffusion assay were compared, and the MBC determined. In addition, the susceptibility to erythromycin of 436 clinical isolates of S. pyogenes from the Leiden region was determined. The microbroth MIC90s of azithromycin, clarithromycin, erythromycin and roxithromycin for group A streptococci were < or = 0.5 mg/L. Erythromycin had the lowest MIC90 (0.09 mg/L). The MIC data obtained with the E-test method suggested that clarithromycin and erythromycin had slightly higher anti-streptococcal activity than azithromycin and roxithromycin in vitro. MICs obtained with the E-test were lower than those found with the microbroth method. Only minor discrepancies were observed among the three methods. The MBC50 for both clarithromycin and erythromycin was 0.75 mg/L and 5.0 mg/L for azithromycin and roxithromycin. None of the 180 strains and two of the collection of 436 strains (0.5%) were resistant to erythromycin and the other macrolides tested; MICs ranged from 1 to 16 mg/L. The erythromycin-resistant strains showed an inducible type of macrolide-lincosamide-streptogramin B (MLS) resistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7563004     DOI: 10.1099/00222615-43-5-386

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  4 in total

1.  Streptococcal pharyngitis: is penicillin still the drug of choice?

Authors:  K R Rajesh; R C Gordon
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

Review 2.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  Susceptibility of group A beta-hemolytic streptococci in the lower St Lawrence region, Quebec.

Authors:  A Desrosiers; P Dolcé; P Jutras; L P Jetté
Journal:  Can J Infect Dis       Date:  1999-07

Review 4.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.